ASCO 2023 | Current therapeutic options for uveal melanoma

Roger Olofsson Bagge, MD, PhD, Gothenburg University, Gothenburg, Sweden, comments on the latest treatment strategies for patients with uveal melanoma. The Phase III trial (NCT03070392) of tebentafusp revealed the bispecific protein to result in longer overall survival. However, uveal melanoma remains an unmet need and more research is required to find more efficacious and durable treatments. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.